ReviewAdvances in experimental medicine and biology2026
Epigenetic alterations in Myeloid Malignancies.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic alterations have emerged as central contributors to the pathogenesis, progression, and therapeutic response in cancer, and in this particular case, which we are discussing, myeloid malignancies. Unlike genetic mutations, epigenetic changes, like DNA methylation and histone modifications, are reversible and dynamic, and this book chapter aims to provide a comprehensive overview of the fundamental principles of epigenetic regulation and explores how these mechanisms are disrupted across different myeloid malignancies. We will examine disease-specific epigenetic landscapes and highlight the key alterations that occur within myeloid malignancies and discuss how such alterations can contribute to leukemogenesis and disease progression. Altogether, this chapter emphasizes the central role of epigenetic dysregulation in shaping the biology and clinical behavior of myeloid malignancies.
Indexed as
Identifiers
42435176What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.